Entecavir
| Evidence Level: L5 | Predicted Indications: 50 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Entecavir |
| DrugBank ID | DB00442 |
| Brand Names (EU) | Entecavir Accord |
| Evidence Level | L5 |
| Predicted Indications | 50 |
| Top Prediction Score | 99.98% |
Approved Indication (EMA)
Entecavir Accord is indicated for the treatment of chronic hepatitis B virus (HBV) infection in adults with: compensated liver disease and evidence of active viral replication, persistently elevated serum alanine aminotransferase (ALT) levels and histological evidence of active inflammation and/or fibrosis. decompensated liver disease. For both compensated and decompensated liver disease, this indication is based on clinical trial data in nucleoside naive patients with HBeAg positive and HBeAg
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | chronic hepatitis C virus infection | 99.98% | DL |
| 2 | hepatitis B virus infection | 99.85% | DL |
| 3 | HIV infectious disease | 99.80% | DL |
| 4 | hepatitis C virus infection | 99.69% | DL |
| 5 | chronic hepatitis B virus infection | 99.67% | DL |
| 6 | simian immunodeficiency virus infection | 99.65% | DL |
| 7 | feline acquired immunodeficiency syndrome | 99.65% | DL |
| 8 | neurodevelopmental disorder with ataxic gait, absent speech, and decreased cortical white matter | 99.64% | DL |
| 9 | hepatitis, viral, animal | 99.46% | DL |
| 10 | hepatitis E virus infection | 99.45% | DL |
| 11 | hepatitis A virus infection | 99.44% | DL |
| 12 | Omsk hemorrhagic fever | 99.41% | DL |
| 13 | Kyasanur forest disease | 99.39% | DL |
| 14 | early-onset familial noncirrhotic portal hypertension | 97.94% | DL |
| 15 | hepatoportal sclerosis | 97.94% | DL |
| 16 | hepatopulmonary syndrome | 97.94% | DL |
| 17 | idiopathic copper-associated cirrhosis | 97.94% | DL |
| 18 | primitive portal vein thrombosis | 97.94% | DL |
| 19 | obsolete familial combined hyperlipidemia | 97.64% | DL |
| 20 | hepatic porphyria | 97.39% | DL |
Showing top 20 of 50 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.